

JZL 184

Catalog No: tcsc3373



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1101854-58-3

Formula:

$C_{27}H_{24}N_2O_9$

Pathway:

Metabolic Enzyme/Protease

Target:

MAGL

Purity / Grade:

>98%

Solubility:

DMSO : \geq 35 mg/mL (67.24 mM)

Observed Molecular Weight:

520.49

Product Description


JZL 184 is a potent and selective inhibitor of MAGL with IC₅₀ of 8 nM and 4 μ M for inhibition of MAGL and FAAH in mouse brain membranes respectively.

IC50 value: 8 nM [1]

Target: MAGL inhibitor

in vitro: JZL184 prolongs DSE in Purkinje neurons in cerebellar slices and DSI in CA1 pyramidal neurons in hippocampal slices. JZL184 is more potent in inhibiting mouse MAGL than rat MAGL [2].

in vivo: When administered to mice at 16 mg/kg, intraperitoneally, JZL 184 reduces MAGL activity by 85%, elevates brain 2-AG levels by 8-fold, and elicits analgesic activity in a variety of pain assays that qualitatively mimics direct central cannabinoid (CB1) agonists [1]. Acute administration of JZL184 to FAAH(-/-) mice enhanced the magnitude of a subset of cannabimimetic responses, repeated JZL184 treatment led to tolerance to its antinociceptive effects, cross-tolerance to the pharmacological effects of $\Delta(9)$ -tetrahydrocannabinol, decreases in CB1 receptor agonist-stimulated guanosine 5'-O-(3-[(35)S]thio)triphosphate binding, and dependence as indicated by rimonabant-precipitated withdrawal behaviors, regardless of genotype [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!